The National Authority of Medicines (Infarmed) has suspended the sale of certain batches of Duloxetina toLife, which is prescribed for the treatment of depression.
In an informative notice, Infarmed stated that some batches in 30 mg and 60 mg dosages will be recalled—see the table below—due to “a clinical result above acceptable limits for an impurity.”
As a result, “entities possessing these medication batches in stock must not sell, dispense, or administer them and should arrange for their return.”
Patients using medicines from these batches “should not stop their treatment.” Therefore, “as soon as possible, they should contact their doctor to determine if substitution with an alternative medication is necessary.”
© Infarmed
